Thrombophilia work-up and clinical outcomes in Indian patients with unprovoked venous and arterial thrombosis aged 18-50 years | BTVB Bioequivalence of von Willebrand factor-containing concentrates: implications for von Willebrand disease | BTVB Cardiovascular risk in hormone replacement therapy | BTVB Direct oral anticoagulants: does one dose fit all? Why, when and how testing | BTVB Cardiovascular risk profile evolution over 15 years: CV-PREVITAL vs Moli-sani Study | BTVB Launch of National Registry for Congenital Hematological Disorders in Palestine: Haemo-PAL | BTVB

This journal has not published any issues.

Impact Factor 2025

Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

By Issue

Search Results

##search.searchResults.foundPlural##

Development and implementation of a mathematical model for inpatient warfarin dosing: rationale and methods

Nikolaos Tsaftaridis, Mark Goldin, Kanta Ochani, Todd Levy, Theodoros P. Zanos, Alex C. Spyropoulos

28-08-2026

https://doi.org/10.4081/btvb.2026.195

0

PDF: 0
PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508^CAT O. Milberg¹, H. Abdallah¹, R.K. Lokken², R. Dingman¹, K.A. Meagher¹, P. Banerjee¹, M.E. Burczynski¹, E. Marin¹, A.P. Kithcart¹, D.E. Gutstein¹ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Allucent, Cary, NC, USA

ICTHIC 2026

16-04-2026

https://doi.org/10.4081/btvb.2026.544

372

PDF: 103

1 - 2 of 2 items

© PAGEPress 2008-2026 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.